Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 8/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614642 | 1.00 | NR1H2 (0.41) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL31565399 | 0.85 | ESR2 (0.40) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL3881781 | 0.85 | GRM5 (0.42) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL3881785 | 0.85 | GRM5 (0.42) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL29915399 | 0.84 | NR1H2 (0.42) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL31669964 | 0.84 | ESR2 (0.36) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL3880132 | 0.83 | NR1H2 (0.41) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL3880129 | 0.83 | NR1H2 (0.41) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL3878421 | 0.82 | NR1H2 (0.41) | NR1H2GRM5USP2SMN1; SMN2ESR2 | |
| SCHEMBL3878423 | 0.82 | NR1H2 (0.41) | NR1H2GRM5USP2SMN1; SMN2ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS, INCORPORATED | 2023-03-16 | — | — | US | disclosed |
| WO-2022099117-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230083376-A1 | BRM Targeting Compounds And Associated Methods Of Use | ADRM1, BRDT, RBX1 | NR1H2 2591/4885GRM5 1714/4885USP2 55/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | NR1H2 2591/4885GRM5 1714/4885USP2 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.